

Jin-Hee Ahn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9572477/publications.pdf>

Version: 2024-02-01

90
papers

1,453
citations

394421

19
h-index

361022

35
g-index

94
all docs

94
docs citations

94
times ranked

2935
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. <i>Cancer Research and Treatment</i> , 2022, 54, 469-477.	3.0	5
2	CT Findings From Interstitial Lung Diseases in Patients With Metastatic Breast Cancer Treated With Fam-Trastuzumab Deruxtecan: A Single Institutional Experience. <i>Journal of Breast Cancer</i> , 2022, 25, 49.	1.9	4
3	Whole-Genome and Transcriptome Sequencing Identified NOTCH2 and HES1 as Potential Markers of Response to Imatinib in Desmoid Tumor (Aggressive Fibromatosis): A Phase II Trial Study. <i>Cancer Research and Treatment</i> , 2022, 54, 1240-1255.	3.0	4
4	Abstract GS1-01: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses. <i>Cancer Research</i> , 2022, 82, GS1-01-GS1-01.	0.9	5
5	The impact of systematic assessment for adverse events on unscheduled hospital utilization in patients receiving neoadjuvant or adjuvant chemotherapy: A retrospective multicenter study. <i>Cancer Medicine</i> , 2022, 11, 705-714.	2.8	1
6	Association between tumor 18F-fluorodeoxyglucose metabolism and survival in women with estrogen receptor-positive, HER2-negative breast cancer. <i>Scientific Reports</i> , 2022, 12, 7858.	3.3	3
7	Phase II Clinical Trial of Eribulin+Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma. <i>Clinical Cancer Research</i> , 2022, 28, 3225-3234.	7.0	5
8	Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer. <i>JAMA Oncology</i> , 2022, 8, 1271.	7.1	15
9	The role of postoperative radiotherapy after primary tumor resection in patients with de novo stage IV breast cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 495-505.	1.1	6
10	Undervaluation of Radiotherapy for Gross Desmoid Tumors: The Need for Absolute Volume Assessment. <i>In Vivo</i> , 2021, 35, 1777-1784.	1.3	0
11	Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab. <i>Journal of Breast Cancer</i> , 2021, 24, 359.	1.9	4
12	The Role and Clinical Effectiveness of Multiline Chemotherapy in Advanced Desmoplastic Small Round Cell Tumor. <i>Clinical Medicine Insights: Oncology</i> , 2021, 15, 117955492098710.	1.3	1
13	Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study. <i>European Journal of Cancer</i> , 2021, 144, 341-350.	2.8	5
14	Abstract PS13-07: Neoadjuvant adriamycin plus cyclophosphamide followed by docetaxel (AC4-D4) vs 5-fluorouracil, epirubicin plus cyclophosphamide followed by docetaxel (FEC3-D3) in stage II or III operable breast cancer : Randomized phase III neo-shorter trial (NCT02001506). , 2021, , .		0
15	Eribulin and gemcitabine in previously treated patients with advanced liposarcoma or leiomyosarcoma: A multicenter, single-arm, phase 2-trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11516-11516.	1.6	1
16	Final results of the randomized phase 2 LEO trial and bone protective effects of everolimus for premenopausal hormone receptor-positive, HER2-negative metastatic breast cancer. <i>International Journal of Cancer</i> , 2021, 149, 917-924.	5.1	5
17	Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer. <i>Scientific Reports</i> , 2021, 11, 10510.	3.3	3
18	Prognostic effects of cytokine levels on patients treated with taxane and zoledronic acid for metastatic breast cancer in bone (BEAT-ZO) (KCSG BR 10-13). <i>Cytokine</i> , 2021, 142, 155487.	3.2	6

#	ARTICLE	IF	CITATIONS
19	Demographics, Changes in Treatment Patterns, and Outcomes of Bone and Soft Tissue Sarcomas in Koreaâ€”A Sarcoma-Specific, Institutional Registry-Based Analysis. <i>Cancer Management and Research</i> , 2021, Volume 13, 8795-8802.	1.9	1
20	Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study). <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110619.	3.2	4
21	Plasma Proteome Signature to Predict the Outcome of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy. <i>Cancers</i> , 2021, 13, 6267.	3.7	7
22	How Cancer Patients Perceive Clinical Trials (CTs) in the Era of CTs: Current Perception and Its Differences Between Common and Rare Cancers. <i>Journal of Cancer Education</i> , 2020, 35, 545-556.	1.3	1
23	Characteristics of metastatic brachial plexopathy in patients with breast cancer. <i>Supportive Care in Cancer</i> , 2020, 28, 1913-1918.	2.2	17
24	Is asymptomatic surveillance beneficial after standard treatment? A 10â€”year survival analysis of recurrent BC patients by detection method of recurrence. <i>Breast Journal</i> , 2020, 26, 556-559.	1.0	1
25	A pilot study on intermittent every other days of 5-dose Filgrastim compared with single Pegfilgrastim in breast Cancer patients receiving adjuvant Docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy. <i>Investigational New Drugs</i> , 2020, 38, 866-873.	2.6	2
26	Analysis of the serial circulating tumor cell count during neoadjuvant chemotherapy in breast cancer patients. <i>Scientific Reports</i> , 2020, 10, 17466.	3.3	11
27	Predictive Role of TP53, PIK3CA and MLL2 in ER+ HER2+ Breast Cancer: Biomarker Analysis of Neo-ALL-IN [NCT 01275859]. <i>Anticancer Research</i> , 2020, 40, 5883-5893.	1.1	1
28	The clinical outcomes of undifferentiated pleomorphic sarcoma (UPS): A single-centre experience of two decades with the assessment of PD-L1 expressions. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1287-1293.	1.0	11
29	Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study. <i>Targeted Oncology</i> , 2020, 15, 485-493.	3.6	6
30	A phase I study of TGF- β 2 inhibitor, vactosertib in combination with imatinib in patients with advanced desmoid tumor (aggressive fibromatosis).. <i>Journal of Clinical Oncology</i> , 2020, 38, 11557-11557.	1.6	6
31	A Propensity Score-matched Analysis of Long-term Oncologic Outcomes After Nipple-sparing Versus Conventional Mastectomy for Locally Advanced Breast Cancer. <i>Annals of Surgery</i> , 2020, Publish Ahead of Print, .	4.2	10
32	Clinical outcomes of angiosarcoma: a single institution experience. <i>Cancer Communications</i> , 2019, 39, 1-4.	9.2	4
33	The pretreatment erythrocyte sedimentation rate predicts survival outcomes after surgery and adjuvant radiotherapy for extremity soft tissue sarcoma. <i>Radiation Oncology</i> , 2019, 14, 116.	2.7	12
34	Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2+ metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16). <i>British Journal of Cancer</i> , 2019, 121, 985-990.	6.4	9
35	Intrinsic Prognostic Impact of Tumor-infiltrating Lymphocytes in Systemically Untreated Patients With Early-stage Triple-negative Breast Cancer. <i>Anticancer Research</i> , 2019, 39, 3111-3119.	1.1	12
36	Quality of life outcomes including neuropathyâ€”associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as firstâ€”line chemotherapy for HER2â€”negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG) Tj ETQq0 0 0 rgt /Overlock 10 T	9.2	5

#	ARTICLE	IF	CITATIONS
37	Diagnostic accuracy and safety of ^{18}F -[^{18}F]fluoro- $^{17}\beta$ -oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study. <i>Lancet Oncology</i> , The, 2019, 20, 546-555.	10.7	85
38	Clinical Implication of HER2 Status in Hormone Receptor-Positive Mucinous Breast Cancer. <i>Annals of Surgical Oncology</i> , 2019, 26, 2166-2174.	1.5	12
39	Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01). <i>Cancer Research and Treatment</i> , 2019, 51, 43-52.	3.0	34
40	Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study). <i>European Journal of Cancer</i> , 2018, 103, 127-136.	2.8	10
41	<i>FCR3A</i> -158 Polymorphism and Stromal Tumor-Infiltrating Lymphocytes and Survival among Patients with Metastatic HER2-Positive Breast Cancer Receiving Trastuzumab-Based Treatment. <i>Journal of Breast Cancer</i> , 2018, 21, 45.	1.9	0
42	How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies. <i>ESMO Open</i> , 2018, 3, e000357.	4.5	112
43	Elucidating therapeutic molecular targets in premenopausal Asian women with recurrent breast cancers. <i>Npj Breast Cancer</i> , 2018, 4, 19.	5.2	19
44	A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial. <i>International Journal of Cancer</i> , 2018, 143, 3240-3247.	5.1	46
45	Efficacy of assessing circulating cell-free DNA using a simple fluorescence assay in patients with triple-negative breast cancer receiving neoadjuvant chemotherapy: a prospective observational study. <i>Oncotarget</i> , 2018, 9, 3875-3886.	1.8	9
46	Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study. <i>Cancer Research and Treatment</i> , 2018, 50, 175-182.	3.0	18
47	Quality of life(QoL) outcomes including neuropathy associated scale (FACT-T) from a phase II, multicenter, randomized trial of eribulin plus gemcitabine(EG) versus paclitaxel plus gemcitabine(PG) as first-line chemotherapy for human epidermal growth factor receptor 2 (HER2)- negative metastatic breast cancer(MBC): Korean Cancer Study Group trial (KCSG BR13-11).. <i>Journal of Clinical Oncology</i> , 2018, 36, 10117-10117.	1.6	0
48	Quality of life on TSU-68: Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, 365-371.	1.1	0
49	Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer. <i>European Journal of Cancer</i> , 2017, 86, 385-393.	2.8	23
50	A Randomized Feasibility Study of ^{18}F -Fluoroestradiol PET to Predict Pathologic Response to Neoadjuvant Therapy in Estrogen Receptor-Rich Postmenopausal Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 563-568.	5.0	40
51	Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET-amplified gastric cancer. <i>Oncotarget</i> , 2017, 8, 79546-79555.	1.8	21
52	A randomized, double-blind, phase III study comparing SB3 (trastuzumab biosimilar) with originator trastuzumab in patients treated by neoadjuvant therapy for HER2-positive early breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 509-509.	1.6	11
53	Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus. <i>Oncotarget</i> , 2016, 7, 10547-10556.	1.8	52
54	Expression of FOXM1 and related proteins in breast cancer molecular subtypes. <i>International Journal of Experimental Pathology</i> , 2016, 97, 170-177.	1.3	43

#	ARTICLE	IF	CITATIONS
55	Monogenic and polygenic determinants of sarcoma risk: an international genetic study. <i>Lancet Oncology</i> , 2016, 17, 1261-1271.	10.7	161
56	Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential significant biomarkers. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 685-695.	2.3	20
57	Clinical significance of fatty liver disease induced by tamoxifen and toremifene in breast cancer patients. <i>Breast</i> , 2016, 28, 67-72.	2.2	33
58	Prognostic tissue biomarker exploration for patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors. <i>Tumor Biology</i> , 2016, 37, 4919-4927.	1.8	6
59	Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 339-347.	2.3	4
60	Differential expression of major histocompatibility complex class I in subtypes of breast cancer is associated with estrogen receptor and interferon signaling. <i>Oncotarget</i> , 2016, 7, 30119-30132.	1.8	62
61	Postoperative Radiotherapy After Limb-sparing Surgery for Soft-tissue Sarcomas of the Distal Extremities. <i>Anticancer Research</i> , 2016, 36, 4825-4832.	1.1	6
62	Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study. <i>Cancer Research and Treatment</i> , 2016, 48, 1373-1381.	3.0	9
63	Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer. <i>Cancer Research and Treatment</i> , 2016, 48, 499-507.	3.0	0
64	Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naïve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenocarcinoma or mutated EGFR. <i>BMC Cancer</i> , 2015, 15, 763.	2.6	18
65	A phase 1 study of a heterologous prime-boost vaccination involving a truncated HER2 sequence in patients with HER2-expressing breast cancer. <i>Molecular Therapy - Methods and Clinical Development</i> , 2015, 2, 15031.	4.1	6
66	Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers. <i>PLoS ONE</i> , 2015, 10, e0137885.	2.5	20
67	Pulmonary Metastasectomy Could Prolong Overall Survival in Select Cases of Metastatic Urinary Tract Cancer. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e297-e304.	1.9	28
68	Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab. <i>American Journal of Clinical Pathology</i> , 2015, 144, 278-288.	0.7	103
69	Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab. <i>American Journal of Clinical Pathology</i> , 2015, 144, 570-578.	0.7	52
70	High mobility group B1 and N1 (HMGB1 and HMGN1) are associated with tumor-infiltrating lymphocytes in HER2-positive breast cancers. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 467, 701-709.	2.8	25
71	Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02). <i>Breast Cancer Research and Treatment</i> , 2015, 152, 77-85.	2.5	17
72	A Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast Cancer. <i>Cancer Research and Treatment</i> , 2015, 47, 406-415.	3.0	6

#	ARTICLE	IF	CITATIONS
73	Prognostic biomarker exploration for patients with metastatic renal cell carcinoma receiving VEGFR TKI.. Journal of Clinical Oncology, 2015, 33, 491-491.	1.6	0
74	Clinical outcome of patients with metastatic renal cell carcinoma who interrupted VEGFR-TKI after achieving stable disease or better response.. Journal of Clinical Oncology, 2015, 33, 459-459.	1.6	0
75	Next-generation sequencing to reveal somatic mutations that confer sensitivity to everolimus.. Journal of Clinical Oncology, 2015, 33, 11010-11010.	1.6	0
76	MET expression is associated with disease-specific survival in breast cancer patients in the neoadjuvant setting. Pathology Research and Practice, 2014, 210, 494-500.	2.3	9
77	Efficacy and Safety of Everolimus in Korean Patients with Metastatic Renal Cell Carcinoma Following Treatment Failure with a Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor. Cancer Research and Treatment, 2014, 46, 339-347.	3.0	5
78	Changes of pulmonary function test and development of non-infectious pneumonitis in patients with metastatic renal cell carcinoma treated with everolimus.. Journal of Clinical Oncology, 2014, 32, 530-530.	1.6	0
79	Active surveillance as a treatment option for metastatic or recurrent renal cell carcinoma.. Journal of Clinical Oncology, 2014, 32, 426-426.	1.6	0
80	LUX-breast 1: Randomized, phase III trial of afatinib and vinorelbine versus trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment.. Journal of Clinical Oncology, 2012, 30, TPS649-TPS649.	1.6	11
81	Predictive factors of no response during neoadjuvant chemotherapy in breast cancer.. Journal of Clinical Oncology, 2012, 30, e11508-e11508.	1.6	0
82	Safety and efficacy of everolimus in Asian patients with metastatic renal cell carcinoma (mRCC) who failed previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy: A subanalysis of REACT.. Journal of Clinical Oncology, 2012, 30, e15064-e15064.	1.6	1
83	Bilateral Extraocular Muscle Metastasis of Nasal Rhabdomyosarcoma Mimicking a Thyroid Associated Orbitopathy: A Case Report. Journal of the Korean Society of Magnetic Resonance in Medicine, 2011, 15, 176.	0.1	2
84	Docetaxel and cisplatin combination chemotherapy in metastatic breast cancer patients with previous exposure to anthracyclines. Breast, 2005, 14, 304-309.	2.2	16
85	Epidermal Growth Factor Receptor (EGFR) Expression in Operable Non-small Cell Lung Carcinoma. Journal of Korean Medical Science, 2004, 19, 529.	2.5	11
86	Alternative Therapy and Abnormal Liver Function During Adjuvant Chemotherapy in Breast Cancer Patients. Journal of Korean Medical Science, 2004, 19, 397.	2.5	16
87	Capecitabine and Vinorelbine in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane. Journal of Korean Medical Science, 2004, 19, 547.	2.5	40
88	Clinical Value of Cyclooxygenase-2 Expression in Human Breast Carcinoma. Cancer Research and Treatment, 2004, 36, 192.	3.0	3
89	Oral Doxifluridine Plus Leucovorin in Metastatic Colorectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, 98-102.	1.3	7
90	Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer. Cancer Chemotherapy and Pharmacology, 2002, 50, 104-110.	2.3	28